MEDANTABSEGlobal Health LtdHighNeutral
Announced Thu, 14 May · 16:57 IST

Intimation of Outcome of Board Meeting for Recommending Final Dividend.

Revenue Growth 20pctPat Growth 25pctExceptional ItemAuditor Mid Year ChangeResults View source PDF

MEDANTA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+2.4%1-day move
₹1210.30
prior close
₹1234.00
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.2-0.5+0.3+0.1+2.4+2.0+1.9+2.5+2.1+1.5-0.0+0.3+10.9
Up moveDown movePending
AI summary

Global Health Ltd (Medanta) reported FY26 consolidated revenue of Rs 44,102.66 million, up 19.4% from Rs 36,923.45 million in FY25. Profit after tax grew 15.1% to Rs 5,540.68 million from Rs 4,813.18 million. Basic EPS improved to Rs 20.71 from Rs 17.92. The Board recommended a final dividend of Rs 0.50 per share (25% on face value of Rs 2), subject to shareholder approval at AGM. Statutory auditors Walker Chandiok & Co LLP issued an unmodified opinion with no qualifications. Exceptional items of Rs 10.21 million net include impact of new labour codes (Rs 365.98 million charge), partially offset by reversal of EPCG interest liability (Rs 195.92 million) and stamp duty reversal (Rs 159.85 million).

Likely market impact

The company delivered strong double-digit revenue and PAT growth with an unmodified auditor opinion, signalling financial health. The dividend recommendation reinforces confidence in cash generation. Revenue growth near the 20% threshold could attract growth-focused investors.